Merck to Acquire Cidara Therapeutics Inc Diversifying Its Portfolio To Include Late-Phase Antiviral Agent

Today’s Highlights November 14, 2025

Merck to Acquire Cidara Therapeutics
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (Nasdaq: This content is for paid subscribers.

Please click here to subscribe or here to log in.

Today’s Highlights

Cidara Therapeutics (CDTX), Merck (MRK)

November 14, 2025

Exclusive Market Insight

& Scientific analysis

Merck to Acquire Cidara Therapeutics Inc Diversifying Its Portfolio To Include Late-Phase Antiviral Agent

Other Articles